Journal
TRENDS IN PARASITOLOGY
Volume 26, Issue 3, Pages 119-124Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2009.12.007
Keywords
-
Categories
Funding
- National Center for Research Resources [KL2RR025746]
- UK Health Protection Agency
- NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025746] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI076785] Funding Source: NIH RePORTER
Ask authors/readers for more resources
During follow-up in antimalarial drug trials, treated subjects can be newly infected. PCR correction is used to distinguish this re-infection from drug failure (recrudescence) and to adjust final drug efficacy estimates. The epidemiological, biological and technical limitations of PCR correction and how this can lead to misclassification in drug trial outcomes are underappreciated. This article considers these limitations and proposes a framework for reporting, interpreting and improving PCR correction of antimalarial trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available